A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) (NCT03989414)

🧪 Interventions in This Study

• CC-92480 (DRUG)
• Bortezomib (DRUG)
• Dexamethasone (DRUG)
• Daratumumab (DRUG)
• Carfilzomib (DRUG)
• Elotuzumab (DRUG)
• Isatuximab (DRUG)
• Carfilzomib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (49 Sites)

Showing the first 25 of 49 sites.

• Local Institution - 119 — Denver, Colorado
• Local Institution - 104 — Tampa, Florida
• Local Institution - 108 — Atlanta, Georgia
• Local Institution - 112 — Chicago, Illinois
• Local Institution - 107 — Chicago, Illinois
• Local Institution - 117 — Boston, Massachusetts
• Local Institution - 101 — Boston, Massachusetts
• Local Institution - 118 — Boston, Massachusetts
• Local Institution - 113 — Detroit, Michigan
• Local Institution - 106 — Rochester, Minnesota
• Hackensack University Medical Center — Hackensack, New Jersey
• Local Institution - 110 — Winston-Salem, North Carolina
• Local Institution - 115 — Columbus, Ohio
• Local Institution - 114 — Nashville, Tennessee
• Local Institution - 116 — Houston, Texas
• Swedish Cancer Institute — Seattle, Washington
• Local Institution - 201 — Calgary, Alberta
• Local Institution - 205 — Edmonton, Alberta
• Local Institution - 204 — Halifax, Nova Scotia
• Local Institution - 203 — Toronto, Ontario
• Local Institution - 202 — Montreal, Quebec
• Local Institution - 802 — Brno,
• Local Institution - 801 — Ostrava-Poruba,
• Local Institution - 803 — Prague,
• Local Institution - 902 — Odense,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Myeloma

• Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
• Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
• MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
• A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
• A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey

Explore by condition: All Multiple Myeloma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.